TIMP1 and plasma cell myeloma: A statistically significant reduction in TIMP1 expression was observed, accompanied by an increase in CD82B and CRISP3 expression, in the myeloma (MM) group with a favorable prognosis compared to the MM group with an unfavorable prognosis (p < 0.05) (Table S3 and Figure 3).